Off-pump coronary artery bypass (OPCAB), or simply beating-heart coronary artery bypass grafting, uses a median sternotomy to access the heart, similar to on-pump coronary artery bypass (ONCAB) procedures. The important difference is that the cardiopulmonary bypass pump is not employed. Clinical studies show that OPCAB offers several benefits compared to ONCAB procedures, including reductions in bleeding, short-term neurocognitive dysfunction, kidney dysfunction and length of hospital stay.
Surgical heart valve replacement procedures can be performed using tissue or mechanical heart valves. Tissue valve procedures can be classified by valve replaced (aortic, mitral, tricuspid or pulmonary), by material (xenograft or allograft) or device type (stented, sutureless or stentless). Mechanical valves can be classified by valve replaced (aortic, mitral, tricuspid or pulmonary) or by conduit (with conduit or without conduit).
Of the four valves in the human heart (mitral valve, tricuspid valve, aortic valve and pulmonary valve), the mitral valve is most prone to regurgitation. This is a condition where blood is funneled back into the left atrium of the heart. Mitral regurgitation (MR) can either be caused by a congenital defect or myxomatous degeneration of the valve.
Ventricular assist devices (VADs) are used to aid a failing heart by supplementing the pumping function of the heart. VADs are often used in patients with advanced heart failure (HF). HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pump power of the heart, which causes the heart to become too weak to pump blood at a level sufficient to meet the body’s demands.
Industry Trends Heart failure affects over five million people annually in the U.S. alone and is the costliest cardiovascular illness, with upwards of $30 billion spent on managing heart failure each year. Cardiac rhythm management devices, such as pacemakers, ICDs and CRT devices, are implanted in patients with arrhythmias to correct cardiac pacing and/or to
The total market for cardiac rhythm management devices in Europe is growing at a rate of 3.9%, which will take the 2018 market value of €2.2 billion up to €2.9 billion by 2025. Reprocessed diagnostic electrophysiology (EP) catheters accounted for a significant percentage of all diagnostic EP catheters used. Reprocessed catheters have a much lower
In 2020, the U.S. peripheral vascular device market size was valued at $7.1 billion, with over 8.26 million peripheral vascular procedures performed each year. The market size is expected to increase and reach $10.4 billion by 2026. Throughout this medical market research, we analyzed 67 peripheral vascular companies across the United States and used our comprehensive
In 2018, the total market for cardiac rhythm management, electrophysiology and ablation devices experienced an increase over the previous year. Since these devices are critical life-saving apparatuses, the aging U.S. population means continued market growth for all market segments in this report, with particularly strong growth in the electrophysiology (EP) and ablation markets. Over the
iData’s global intravascular ultrasound market MedCore covers both the peripheral IVUS market and the coronary IVUS market. Medcores include a highly detailed and in-depth look at a segment in a market with all the associated sub- and sub-sub segments. iData MedCore reports allow users to delve deep into a specific market in order to obtain units sold, average selling prices (ASPs), market values, growth rates, a 10-year forecast including historical and future market estimates, and competitor market shares of any given market segment.
Global TAVI/TAVR, CEPD, and Pre-Shaped Guidewire markets are expected to increase to reach $8.4 billion, $492.3 million, and $70.9 million. The analysis includes in-depth procedure numbers, which will seemingly increase over the forecast period, along with the impact of COVID-19 on the procedure volume.
In 2020, the global pacemaker market size was valued at $2.26 billion, with over 450,000 pacemaker procedures performed annually. The market size is expected to further increase over the forecast period and reach $2.6 billion in 2025. Throughout this medical market research, we analyzed global pacemaker companies across more than 70 countries and used our comprehensive methodology
In 2020, the global central venous catheter (CVC) market size was valued at approximately $763 million, with over 27 million CVC insertion procedures performed every year. The global market size is expected to reach $860 million in 2026. The overwhelming majority of the global central venous catheter market share was controlled by Teleflex, Becton Dickinson,
The global coronary stents market size is estimated to increase over the forecast period to reach more than $6.6 billion in 2027. The majority of the global coronary stents market share was controlled by Boston Scientific, Medtronic and Abbott. Overall, this global market research includes an analysis of coronary stents companies spawning across more than 70 countries
Stents are commonly used as complementary devices during conventional percutaneous transluminal angioplasty (PTA) balloon catheterization in peripheral vascular procedures. The placement of a stent mitigates some complications, such as negative remodeling and elastic recoil effects.